RxDoctor Payments DataLook up a doctor →

Hara Oyedeji, APRN

Psychiatric/Mental Health · Owings Mills, MDNPI 1497279053

Payments from drug & device makers

$779,809in general payments, 2019–2025

Across 1,175 payments — averaging $663.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$278K
  • Neurocrine Biosciences, Inc.$204K
  • E.r. Squibb & Sons, L.L.C.$186K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$62K
  • Teva Pharmaceuticals USA, Inc.$29K
  • Luye Pharma (USA) Ltd.$11K
  • plus $10K from 11 others

What the payments were for

  • Consulting fees$128,30116%
  • Speaking & faculty fees$515,07266%
  • Travel & lodging$102,66513%
  • Food & beverage$33,7204%
  • Education$520%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$779,809 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$8,395
Medicare patients
13
Services billed
89

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate16$130,517
Invega SustennaPaliperidone Palmitate15$49,285
Haloperidol Decanoate15$718
Bupropion XlBupropion Hcl23$413
Aripiprazole20$388
Divalproex Sodium11$376
Trazodone Hcl24$149
Benztropine Mesylate11$145
Duloxetine Hcl14$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$203,614$130,51716 claims
Johnson & JohnsonInvega Sustenna$204$49,28515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.

Other psychiatric/mental health in Owings Mills

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →